These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 12033190)

  • 1. Using abacavir to avoid lipid problems.
    TreatmentUpdate; 2002 Mar; 14(3):6. PubMed ID: 12033190
    [No Abstract]   [Full Text] [Related]  

  • 2. Improvement of HAART-associated insulin resistance and dyslipidemia after replacement of protease inhibitors with abacavir.
    Walli RK; Michl GM; Bogner JR; Goebel FD
    Eur J Med Res; 2001 Oct; 6(10):413-21. PubMed ID: 11698228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study.
    Wolbers M; Opravil M; von Wyl V; Hirschel B; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Battegay M; Yerly S; Günthard H; Bucher HC;
    AIDS; 2007 Oct; 21(16):2201-7. PubMed ID: 18090047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-HIV agents. Abacavir once or twice daily.
    TreatmentUpdate; 2005; 17(5):8. PubMed ID: 17219659
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
    Hill A; Sawyer W
    HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-HIV agents. Abacavir--as good as AZT?
    TreatmentUpdate; 2003 Oct; 15(6):3-4. PubMed ID: 17216861
    [No Abstract]   [Full Text] [Related]  

  • 7. Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study.
    Llibre JM; Bonjoch A; Iribarren J; Galindo MJ; Negredo E; Domingo P; Pérez-Alvarez N; Martinez-Picado J; Schapiro J; Clotet B;
    HIV Med; 2008 Aug; 9(7):508-13. PubMed ID: 18484978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage therapy with abacavir in HIV-1-infected patients with previously documented M184V mutation: a possibility of NRTI recycling.
    Maggiolo F; Callegaro A; Arici C; Quinzan G; Gregis G; Ripamonti D; Tebaldi A; Goglio A; Suter F
    Antivir Ther; 2003 Apr; 8(2):121-6. PubMed ID: 12741624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching to abacavir to reduce fat wasting.
    TreatmentUpdate; 2002 Mar; 14(3):4-5. PubMed ID: 12033189
    [No Abstract]   [Full Text] [Related]  

  • 10. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
    Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
    BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy.
    Maitland D; Jackson A; Osorio J; Mandalia S; Gazzard BG; Moyle GJ;
    HIV Med; 2008 Oct; 9(8):667-72. PubMed ID: 18631255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.
    Pavie J; Porcher R; Torti C; Medrano J; Castagna A; Valin N; Rusconi S; Ammassari A; Ghosn J; Delaugerre C; Molina JM;
    J Antimicrob Chemother; 2011 Oct; 66(10):2372-8. PubMed ID: 21821627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage therapy with abacavir and other reverse transcriptase inhibitors for human immunodeficiency-associated encephalopathy.
    Saavedra-Lozano J; Ramos JT; Sanz F; Navarro ML; de José MI; Martín-Fontelos P; Mellado MJ; Leal JA; Rodriguez C; Luque I; Madison SJ; Irlbeck D; Lanier ER; Ramilo O
    Pediatr Infect Dis J; 2006 Dec; 25(12):1142-52. PubMed ID: 17133160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Abacavir as initial therapy and as a once-daily drug.
    Sax PE
    AIDS Clin Care; 2003 Nov; 15(11):93-4. PubMed ID: 14682271
    [No Abstract]   [Full Text] [Related]  

  • 15. Genotypic and phenotypic nevirapine resistance correlates with virological failure during salvage therapy including abacavir and nevirapine.
    Jørgensen LB; Katzenstein TL; Gerstoft J; Mathiesen LR; Pedersen C; Nielsen C
    Antivir Ther; 2000 Sep; 5(3):187-94. PubMed ID: 11075938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial.
    Matheron S; Descamps D; Boué F; Livrozet JM; Lafeuillade A; Aquilina C; Troisvallets D; Goetschel A; Brun-Vezinet F; Mamet JP; Thiaux C;
    Antivir Ther; 2003 Apr; 8(2):163-71. PubMed ID: 12741629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between abacavir exposure and increased risk for cardiovascular disease in patients with human immunodeficiency virus.
    Schafer JJ; Short WR; Squires KE
    Pharmacotherapy; 2010 Oct; 30(10):1072-83. PubMed ID: 20874044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High rebound of plasma and cellular HIV load after discontinuation of triple combination therapy.
    Jubault V; Burgard M; Le Corfec E; Costagliola D; Rouzioux C; Viard JP
    AIDS; 1998 Dec; 12(17):2358-9. PubMed ID: 9863885
    [No Abstract]   [Full Text] [Related]  

  • 19. Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/ lamivudine-containing HAART regimen.
    Descamps D; Ait-Khaled M; Craig C; Delarue S; Damond F; Collin G; Brun-Vézinet F
    Antivir Ther; 2006; 11(6):701-5. PubMed ID: 17310814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study.
    Henry K; Wallace RJ; Bellman PC; Norris D; Fisher RL; Ross LL; Liao Q; Shaefer MS;
    J Infect Dis; 2001 Feb; 183(4):571-8. PubMed ID: 11170982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.